Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Minimally invasive convection-enhanced delivery of biologics into dorsal root ganglia: validation in the pig model and prospective modeling in humans
Pleticha, Josef, Maus, Timothy P. , Christner, Jodie A., Marsh, Michael P., Lee, Kendall H. , Hooten, W. Michael , Beutler, Andreas S.

Journal of Neurosurgery | July 4, 2014 | Volume: 121 | Issue: 4 | Pages: 851-858

10.3171/2014.6.jns132364 | PMID 24995785 Get It

Dorsal root ganglia (DRG) are critical anatomical structures involved in nociception. Intraganglionic (IG) drug delivery is therefore an important route of administration for novel analgesic therapies. Although IG injection in large animal models is highly desirable for preclinical biodistribution and toxicology studies of new drugs, no method to deliver pharmaceutical agents into the DRG has been reported in any large species. The present study describes a minimally invasive technique of IG agent delivery in domestic swine, one of the most common large animal models. The technique utilizes CT guidance for DRG targeting and a custom-made injection assembly for convectionenhanced delivery (CED) of therapeutic agents directly into DRG parenchyma. The DRG were initially visualized by CT myelography to determine the optimal access route to the DRG. The subsequent IG injection consisted of 3 steps. First, a commercially available guide needle was advanced to a position dorsolateral to the DRG, and the dural root sleeve was punctured, leaving the guide needle contiguous with, but not penetrating, the DRG. Second, the custom-made stepped stylet was inserted through the guide needle into the DRG parenchyma. Third, the stepped stylet was replaced by the custom-made stepped needle, which was used for the IG CED. Initial dye injections performed in pig cadavers confirmed the accuracy of DRG targeting under CT guidance. Intraganglionic administration of adeno-associated virus in vivo resulted in a unilateral transduction of the injected DRG, with 33.5% DRG neurons transduced. Transgene expression was also found in the dorsal root entry zones at the corresponding spinal levels. The results thereby confirm the efficacy of CED by the stepped needle and a selectivity of DRG targeting. Imaging-based modeling of the procedure in humans suggests that IG CED may be translatable to the clinical setting.
Patch Testing With the Standard Series When Receiving Immunosuppressive Medications
Wentworth, Ashley B., Davis, Mark D. P. , Davis, Mark D.P.

Dermatitis® | July 4, 2014 | Volume: 25 | Issue: 4 | Pages: 195-200

10.1097/der.0000000000000048 | PMID 25000238 Get It

Background Debate surrounds the validity of patch testing for allergic contact dermatitis in patients taking immunosuppressants and the extent to which these medications suppress patch test reactions. Previous studies have demonstrated that corticosteroids can suppress immune reactions measured in patch testing. Because immunomodulators are increasingly used, their impact on patch testing also requires evaluation. Objectives This study aimed to report patch test results in patients taking specific immunosuppressants and to review relevant literature. Methods A retrospective review of patients patch tested with the standard series at Mayo Clinic in Rochester, Minnesota, between January 1, 2008, and December 31, 2011, was conducted. Conclusions Positive patch test results occur during methotrexate therapy. How reactions would differ with no immunosuppression is unclear.
Radioisotope Cisternography in Spontaneous CSF Leaks: Interpretations and Misinterpretations
Mokri, Bahram

Headache: The Journal of Head and Face Pain | July 4, 2014 | Volume: 54 | Issue: 8 | Pages: 1358-1368

10.1111/head.12421 | PMID 25041119 Get It

A broadening of the clinical and imaging features of the spontaneous cerebrospinal fluid ( CSF ) leaks is now well recognized, far beyond what was thought only two decades ago. This has resulted in increasing number of patients with atypical and unusual features who, not unexpectedly, are directed to headache specialists and tertiary referral centers. In many cases, obviously the fundamental question of presence or absence of CSF leak will need to be addressed prior to proceeding with further and often more involved, more invasive, and more costly diagnostic and therapeutic considerations. Radioisotope cisternography often proves to be very helpful in these situations by demonstrating reliable, although indirect, evidences of CSF leak while it is less helpful in directly identifying the exact site of the CSF leakage. In this overview article, the expectations from and the limitations of this diagnostic method are described along with some personal observations in the past 25 years.
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS
Zeidan, Amer M. , Lee, Ju‐Whei, Prébet, Thomas , Greenberg, Peter L. , Sun, Zhuoxin , Juckett, Mark, Smith, Mitchell R. , Paietta, Elisabeth , Gabrilove, Janice , Katterling, Rhett P., Tallman, Martin S. , Gore, Steven D. , Lee, Ju‐Whei , Erba, Harry Paul , Prebet, Thomas , Zeidan, Amer M

British Journal of Haematology | July 4, 2014 | Volume: 167 | Issue: 1 | Pages: 62-68

10.1111/bjh.13008 | PMID 24995683 Get It

SummaryReliable clinical or molecular predictors of benefit from azacitidine therapy in patients with myelodysplastic syndromes (MDS) are not defined. Doubling of platelet count at start of second cycle of azacitidine therapy compared to baseline was associated with achieving response and survival advantage in a Dutch cohort. To validate this observation, we analysed a larger cohort of North American patients, whose data was collected in a prospective clinical trial with a longer median follow‐up. We found a significant association between platelet count doubling after first cycle of azacitidine therapy and probability of achieving objective response. Among patients with MDS or oligoblastic acute myeloid leukaemia (<30% bone marrow blasts, n = 102), there was a statistically significant reduction in risk of death for patients who achieved platelet count doubling (n = 23, median OS, 21·0 months) compared to those who did not (n = 79, median OS, 16·7 months, adjusted hazard ratio (no/yes)=1·88, 95% confidence interval, 1·03–3·40, P = 0·04). Nonetheless, the addition of this platelet count doubling variable did not improve the survival prediction provided by the revised International Prognostic Scoring System or the French Prognostic Scoring System. Identification of reliable and consistent predictors for clinical benefit for azacitidine therapy remains an unmet medical need and a top research priority.
Buying into healthy blood vessels: exercise and aging
Joyner, Michael J. , Joyner, Michael J

Journal of Applied Physiology | July 4, 2014 | Volume: 117 | Issue: 5 | Pages: 421-422

10.1152/japplphysiol.00474.2014 | PMID 24994886 Get It

Hsp70–Bag3 Interactions Regulate Cancer-Related Signaling Networks
Colvin, Teresa A., Gabai, Vladimir L. , Calderwood, Stuart K. , Gummuluru, Suryaram , Matchuk, Olga N. , Smirnova, Svetlana G. , Orlova, Nina V. , Замулаева, И. А. , Li, Xiaokai, Young, Zapporah T. , Rauch, Jennifer N. , Gestwicki, Jason E. , Takayama, Shinichi , Sherman, Michael Y. , Gong, Jianlin , Li, Hu , Garcia‐Marcos, Mikel , Sherman, Michael Y.

Cancer Research | July 4, 2014 | Volume: 74 | Issue: 17 | Pages: 4731-4740

10.1158/0008-5472.can-14-0747 | PMID 24994713 Get It

Abstract Bag3, a nucleotide exchange factor of the heat shock protein Hsp70, has been implicated in cell signaling. Here, we report that Bag3 interacts with the SH3 domain of Src, thereby mediating the effects of Hsp70 on Src signaling. Using several complementary approaches, we established that the Hsp70–Bag3 module is a broad-acting regulator of cancer cell signaling by modulating the activity of the transcription factors NF-κB, FoxM1, Hif1α, the translation regulator HuR, and the cell-cycle regulators p21 and survivin. We also identified a small-molecule inhibitor, YM-1, that disrupts the Hsp70–Bag3 interaction. YM-1 mirrored the effects of Hsp70 depletion on these signaling pathways, and in vivo administration of this drug was sufficient to suppress tumor growth in mice. Overall, our results defined Bag3 as a critical factor in Hsp70-modulated signaling and offered a preclinical proof-of-concept that the Hsp70–Bag3 complex may offer an appealing anticancer target. Cancer Res; 74(17); 4731–40. ©2014 AACR.
Extended Antimicrobial Use in Patients Undergoing Percutaneous Nephrolithotomy and Associated Antibiotic Related Complications
Viers, Boyd R. , Cockerill, Patrick, Mehta, Ramila A. , Bergstralh, Eric J., Krambeck, Amy E. , Cockerill, Patrick A, Viers, Boyd R

Journal of Urology | July 3, 2014 | Volume: 192 | Issue: 6 | Pages: 1667-1672

10.1016/j.juro.2014.06.090 | PMID 24998482 Get It

Deleted in Breast Cancer 1 regulates cellular senescence during obesity
Escande, Carlos , Nin, Verónica , Pirtskhalava, Tamar , Chini, Claudia C.S. , Barbosa, Maria Thereza , Mathison, Angela , Tchkonia, Tamar , Kirkland, James L. , Chini, Eduardo N. , Urrutia, Raúl , Mathison, Angela J , Tchkonia, T

Aging Cell | July 3, 2014 | Volume: 13 | Issue: 5 | Pages: 951-953

10.1111/acel.12235 | PMID 24992635 Get It

SummaryChronic obesity leads to inflammation, tissue dysfunction, and cellular senescence. It was proposed that cellular senescence during obesity and aging drives inflammation and dysfunction. Consistent with this, clearance of senescent cells increases healthspan in progeroid mice. Here, we show that the protein Deleted in Breast Cancer‐1 (DBC1) regulates cellular senescence during obesity. Deletion of DBC1 protects preadipocytes against cellular senescence and senescence‐driven inflammation. Furthermore, we show protection against cellular senescence in DBC1 KO mice during obesity. Finally, we found that DBC1 participates in the onset of cellular senescence in response to cell damage by mechanism that involves binding and inhibition of HDAC3. We propose that by regulating HDAC3 activity during cellular damage, DBC1 participates in the fate decision that leads to the establishment of cellular senescence and consequently to inflammation and tissue dysfunction during obesity.
Propofol monotherapy for neonatal intubation provides high risk but few benefits
Kudchadkar, Sapna R. , Nemergut, Michael E.

Acta Paediatrica | July 3, 2014 | Volume: 103 | Issue: 11 | Pages: No page available

10.1111/apa.12733 | PMID 24990432 Get It

Association Studies of Fcγ Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831
Norton, Nadine , Olson, Rebecca M. , Pegram, Mark D. , Tenner, Kathleen , Clynes, Raphael , Knutson, Keith L. , Perez, Edith A. , Ballman, Karla V. , Knutson, Keith L. , Norton, Nadine

Cancer Immunology Research | July 3, 2014 | Volume: 2 | Issue: 10 | Pages: 962-969

10.1158/2326-6066.cir-14-0059 | PMID 24989892 Get It

Abstract Patients with HER2+ breast cancer treated with trastuzumab and chemotherapy have superior survival compared with patients treated with chemotherapy alone. Polymorphisms within FCGR2A and FCGR3A are associated with binding affinity of natural killer cells to the IgG1 portion of trastuzumab, and a polymorphism in FCGR2B (I232T) is associated with impaired regulatory activity. The association of these polymorphisms with clinical response among trastuzumab-treated patients is equivocal, with both positive and negative associations. We performed genotyping analysis on the FCGR3A V158F, FCGR2A R131H, and FCGR2B I232T polymorphisms in 1,325 patients from the N9831 clinical trial. Patients in arm A (N = 419) received chemotherapy only. Patients in arms B (N = 469) and C (N = 437) were treated with chemotherapy and trastuzumab (sequentially in arm B and concurrently in arm C). Using log-rank test and Cox proportional hazard models, we compared disease-free survival (DFS) among genotypic groups within pooled arms B/C. We found no differences in DFS between trastuzumab-treated patients who had the FCGR3A 158 V/V and/or FCGR2A 131 H/H high-affinity genotypes and patients without those genotypes. Furthermore, there was no significant interaction between FCGR3A and FCGR2A and treatment. However, there was a difference in DFS for FCGR2B I232T, with I/I patients deriving benefit from trastuzumab (P &lt; 0.001), compared with the T carriers who did not (P = 0.81). The interaction between FCGR2B genotype and treatment was statistically significant (P = 0.03). Our analysis did not reveal an association between FcγR high-affinity genotypes and outcomes. However, it seems that the FCGR2B inhibitory gene may be predictive of adjuvant trastuzumab benefit. Cancer Immunol Res; 2(10); 962–9. ©2014 AACR.